4[4]Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-aaalysis[J].J Clin Oncol,2002,20(4):1248-1259.
2Garc a-Velloso MJ,Jurado M,Ceamanos C,et al.Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma[J].Eur J Nucl Med Mol Imaging,2007,34:1396-1405.
3Elit L,Zitzelsberger L,Fung-Kee-Fung M,et al.Use of systemic therapy in women with recurrent ovarian cancer-development of a national clinical practice guideline[J].Gyneeol Oncd,2007,106:181-192.
4Salani R,Santillan A,Zahurak ML,et al.Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer[J].Cancer,2007,109(4):685-691.
5Tebos SJ,Sayer BA,Palmer JM,et al.Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma[J].Gynecol Oncol,2007,106:482-487.
6Perez-Gracia JL,Carrasco EM.Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings:systematic rcview of the literature and implications for future research[J].Gynecol Oncol,2002,84:201-209.
7Wilailak S,Linasmita V,Srisupundit S.Phase Ⅱ study of highdose megestrol acetate in platinum-refractory epithelial ovarian cancer[J].Anticancer Drugs,2001,12:719-724.
8Gnmdker C,Emons G.Role of gonadotropin-releasing hormone(GnRH)in ovarian cancer[J].Reprod Biol Endocrinol,2003,1:65-68.
9Verschraegen CF,Westphalen S,HuW,et al.Phase Ⅱstudy of cetrorelix,a Inteinizing hormone-releasing hormone antagonist in patient with platinum-resistant ovarian cancer[J].Gynecol Oncol,2003,90:552-559.
10Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20(5): 1248 - 1259.
2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10-29.
3Serov SF, Scully RE, Sobin LH. Histologic Typing of Ovari- an Tumors. 9th ed. Geneva: World Health Organization; 1973. International histologie classification of tumors, 1973: 17-18.
4Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol, 2009, 4: 287- 313.
5Robert J, Kurman MD, Kala V, et al. Early detection and treatment of ovarian cancer: shifting from early stage to min- imal volume of disease based on a new model of carcinogene- sis. AmJ Obstet Gynecol, 2008, 198: 351-356.
6Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol, 2012, 126: 481-90.
7Von GR, Franke FE, Munsted TK. Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas. Eur J Obstet Gy- necol Reprod Biol, 2003, 111: 189- 196.
8Tentes AA, Mirelis CG, Markakidis SK. Long- term surviv- al in advanced ovarian carcinoma following cytoreductive sur- gery with standard peritoneotomy procedures. Int J Gynecol Cancer, 2006, 16: 490-495.
